Semaglutide
aka Semaglutide (GLP-1 agonist)
Mechanism
Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes management and chronic weight management. It mimics the incretin hormone GLP-1 to regulate appetite and glucose metabolism.
Identification
| CAS number | 910463-68-2 |
|---|---|
| Molecular formula | C187H291N45O59 |
| Typical dose | 0.25–2.4 mg (250–2400 mcg) subcutaneous once weekly; typically titrated from 0.25 mg/week, increasing every 4 weeks |
| Half-life | ~7 days |
Vendors selling Semaglutide
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Peptide Partners | 50 mg | $335.00 | — | 99 |
| Orbitrex Peptides | 10 mg | $69.99 | — | 95 |
| Orbitrex Peptides | 20 mg | $119.99 | — | 95 |
| Profound Aminos | 5 mg | $79.00 | — | 95 |
| Prime Peptides | 5 mg | $80.00 | — | 95 |
| Prime Peptides | 10 mg | $80.00 | — | 95 |
| Prime Peptides | 15 mg | $80.00 | — | 95 |
| Skye Peptides | 6 mg | $60.00 | — | 90 |
| Qihang Peptide | — | — | — | 87 |
| Peptidegurus | 3 mg | — | — | 84 |
| Peptidegurus | 4 mg | — | — | 84 |
| Peptidegurus | 5 mg | — | — | 84 |
| Peptidegurus | 6 mg | — | — | 84 |
| Peptidegurus | 10 mg | — | — | 84 |
| Reta Peptide | — | $188.00 | — | 83 |
| Reta Peptide | 10 mg | $65.00 | — | 83 |
| Cocer Peptides | 5 mg | $80.00 | — | 82 |
| Blank Peptides | 10 mg | $105.00 | — | 81 |
| Crystal Peptides | 5 mg | $44.99 | — | 66 |
| Crystal Peptides | 10 mg | $79.99 | — | 66 |
| Nox Amino | 10 mg | $95.00 | — | 55 |
| Peptiatlas | 20 mg | — | — | 51 |
| Peptiatlas | — | — | — | 51 |
| Taishijie | — | — | — | 51 |
| Taikangbio | — | — | — | 50 |
| Zjpeptix | — | — | — | 50 |
| Hkuppeptide | 20 mg | $10.00 | — | 50 |
| Hkuppeptide | 10 mg | $10.00 | — | 50 |
| Hkuppeptide | 15 mg | $10.00 | — | 50 |
| Hkuppeptide | 20 mg | $10.00 | — | 50 |
| Hkuppeptide | 10 mg | $10.00 | — | 50 |
| MEI-PEPETIDE | 2 mg | $45.00 | — | 48 |
| DongCheng Peptide | — | — | — | 46 |
| Mandy | 5 mg | $26.00 | — | 43 |
| HongDa Peptide | — | $40.00 | — | 43 |
| zztai Peptide Ltd | 5 mg | $46.00 | — | 43 |
| zztai Peptide Ltd | 10 mg | $53.00 | — | 43 |
| zztai Peptide Ltd | 15 mg | $68.00 | — | 43 |
| zztai Peptide Ltd | 20 mg | $87.00 | — | 43 |
| zztai Peptide Ltd | 30 mg | $116.00 | — | 43 |
| MJT peptides | 5 mg | $37.00 | — | 39 |
| HK Peptide Ltd (hk peptides) | 10 mg | $60.00 | — | 37 |
| Bulk Peptides | 10 mg | $180.00 | — | — |
| Polaris Peptides | 20 mg | $165.00 | — | — |
| Polaris Peptides | 12.5 mg | $105.00 | — | — |
| Polaris Peptides | 5 mg | $50.00 | — | — |
| Polaris Peptides | 2 mg | $30.00 | — | — |
| Polaris Peptides | 10 mg | $90.00 | — | — |
Research
Background This phase 2 study evaluated once-weekly zalfermin and semaglutide for efficacy and safety in patients with metabolic dysfunction-associated steatohepatitis and clinically significant fibrosis, including patients with compensated cirrhosis (F4c).
source →Background To compare sleeve gastrectomy, semaglutide therapy, and the Diet, Exercise, Accompany and Refresh (DEAR) weight management programme for weight control, metabolic improvement, and oncological outcomes in patients with endometrial cancer receiving fertility-sparing treatment.
source →Type 2 diabetes mellitus (T2DM) is associated with an increased risk of mild cognitive impairment (MCI) and dementia. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide cardiovascular and metabolic benefits, and emerging data suggest neurocognitive effects.
source →Background Semaglutide, a glucagon-like peptide-1 receptor agonist, effectively promotes weight loss and improves metabolic parameters in individuals with obesity. However, its use is often accompanied by reductions in lean mass, raising concerns about long-term muscle health.
source →Background With the advancement of proteomics technologies, an increasing number of studies have begun to examine semaglutide-associated protein expression changes and pathway alterations across different biological contexts.
source →Background Obesity is a chronic, progressive disease affecting over 1 billion adults worldwide, linked to serious comorbidities, including diabetes, hypertension, and cardiovascular disease and associated with increased mortality. Achieving clinically meaningful weight loss is critical to reducing cardiometabolic risk.
source →Importance Concerns regarding weight changes during hormonal contraceptive use may influence health care-seeking behavior and contraceptive use patterns.
source →Aims Attaining target glycaemia can be a challenge in Type 1 Diabetes (T1D) due to insulin-induced weight gain. Adjunct therapy with modern glucose-lowering agents developed for type 2 diabetes (T2D) has great potential but may be insufficiently efficacious and carries risks of hypoglycaemia and ketosis.
source →Background and hypothesis People with schizophrenia are at heightened risk for physical multimorbidity and premature death. Semaglutide improves cardiometabolic outcomes, yet research is limited among individuals with schizophrenia.
source →Aims Neuropsychiatric safety concerns, including depression and suicidal ideation, have emerged during the expanding clinical use of incretin-based therapies for type 2 diabetes mellitus (T2DM) and obesity. However, whether risks differ across successive generations of incretin-based therapies remains uncertain.
source →This retrospective cohort study evaluated whether semaglutide and tirzepatide reduce the risk of falls and femoral fractures in older adults with type 2 diabetes and overweight or obesity. The findings showed significantly lower risks of both outcomes compared with DPP-4 inhibitors.
source →Aim In December 2022, semaglutide injections for weight management were marketed in Denmark. Pre-marketing trials documented high efficacy when adherence to the treatment and the recommended dose titration schedule was followed.
source →Alzheimer's disease (AD) is the most common cause of dementia. Despite major research efforts, effective treatments that slow or stop disease progression remain limited. Growing evidence suggests that inflammation in the brain and the body plays a key role in the onset and progression of AD.
source →The goal of this study is to determine how a drug class called glucagon-like peptide-1 receptor agonists (GLP-1Ra) affects people during an early stage of Type 1 Diabetes undergoing clinical teplizumab treatment.
source →This single-center, retrospective observational cohort study evaluated early changes in non-invasive hepatic and metabolic indices (FIB-4, APRI, HSI, and the triglyceride-glucose \[TyG\] index) in adults with overweight or obesity who received once-weekly subcutaneous semaglutide or tirzepatide for metabolic risk reduc…
source →The goal of this research study is to evaluate the pathophysiologic mechanisms by which genetic variation impacts response to an FDA-approved medication commonly used to treat type 2 diabetes called oral semaglutide (Rybelsus) and to characterize the physiological response to a mixed meal tolerance test (MMTT) before a…
source →Gestational diabetes (GDM) is an important contributor to the increasing prevalence of type 2 diabetes (T2DM). Women with glucose intolerance in early postpartum are a particularly high-risk group with about 50% who will develop T2DM within 5 years after the delivery.
source →Systematic review and meta-analysis of semaglutide for weight loss in obesity without diabetes; consistent, clinically meaningful reductions.
source →Phase 3 RCT (STEP 1): once-weekly semaglutide 2.4 mg produced ~15% mean body-weight reduction vs placebo over 68 weeks in adults with overweight or obesity.
source →RCT (STEP 4): continued semaglutide 2.4 mg maintained weight loss; switching to placebo led to regain, supporting ongoing treatment.
source →This project uses both transcriptomic- and genomic-level data to identify mechanisms of individual responses to glucagon-like peptide-1 (GLP-1) in Mexican-Americans with prediabetes. The GLP-1 hormone is essential for glucose reduction, weight loss, cardiovascular risk reduction, and renal protection.
source →This study will look at the change in body weight from the start to the end of the study. The purpose of the study is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine.
source →This trial is conducted globally. The aim of the trial is to examine the dose range, escalation and efficacy of oral semaglutide in subjects with type 2 diabetes.
source →